De-Risking Early Development Strategies For ADCs, Oligonucleotides, & Radioconjugates

The development of biologics and bioconjugates, particularly Antibody-Drug Conjugates (ADCs), holds immense promise for therapeutic advancements. However, navigating these complex molecules from inception to market presents a multitude of challenges. Stringent design processes, alongside technical hurdles in safety, stability, and scalability, can significantly impede progress. Developers often grapple with achieving both speed and quality throughout this intricate pathway.

Trusted guidance can act as a catalyst, streamlining development and ensuring a successful journey from discovery to Investigational New Drug (IND) application and beyond. By leveraging extensive scientific knowledge, technical expertise, and integrated services encompassing the entire development spectrum, an experienced CDMO can empower developers to implement de-risking strategies that significantly improve both clinical and commercial outcomes for their biologic and bioconjugate programs.

Join a panel of industry leaders from Abzena as they address the challenges that can stall progress. Learn how to ensure a high-quality product while expediting the path from discovery to IND filing and beyond.

The discussion will cover critical topics including developability assessments, lead candidate selection, and strategies to mitigate risks during tech transfer and scale-up. With Abzena's proven approach and decades of experience, you can gain valuable insights to move your program forward and deliver life-saving treatments to patients faster.